Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,956 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: shimizu a. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Effects of zoledronic acid and the association between its efficacy and γδT cells in postmenopausal women with breast cancer treated with preoperative hormonal therapy: a study protocol.
Sumi E, Sugie T, Yoshimura K, Tada H, Ikeda T, Suzuki E, Tanaka Y, Teramukai S, Shimizu A, Toi M, Minato N. Sumi E, et al. Among authors: shimizu a. J Transl Med. 2014 Nov 25;12:310. doi: 10.1186/s12967-014-0310-2. J Transl Med. 2014. PMID: 25421542 Free PMC article. Clinical Trial.
A randomized controlled clinical trial of topical insulin-like growth factor-1 therapy for sudden deafness refractory to systemic corticosteroid treatment.
Nakagawa T, Kumakawa K, Usami S, Hato N, Tabuchi K, Takahashi M, Fujiwara K, Sasaki A, Komune S, Sakamoto T, Hiraumi H, Yamamoto N, Tanaka S, Tada H, Yamamoto M, Yonezawa A, Ito-Ihara T, Ikeda T, Shimizu A, Tabata Y, Ito J. Nakagawa T, et al. Among authors: shimizu a. BMC Med. 2014 Nov 19;12:219. doi: 10.1186/s12916-014-0219-x. BMC Med. 2014. PMID: 25406953 Free PMC article. Clinical Trial.
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I. Hamanishi J, et al. Among authors: shimizu a. J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8. J Clin Oncol. 2015. PMID: 26351349 Clinical Trial.
Prognostic significance of β2-adrenergic receptor expression in patients with surgically resected colorectal cancer.
Ogawa H, Kaira K, Motegi Y, Yokobori T, Takada T, Kato R, Osone K, Takahashi R, Suga K, Ozawa N, Katayama C, Oyama T, Shimizu A, Yao T, Asao T, Saeki H, Shirabe K. Ogawa H, et al. Among authors: shimizu a. Int J Clin Oncol. 2020 Jun;25(6):1137-1144. doi: 10.1007/s10147-020-01645-6. Epub 2020 Mar 17. Int J Clin Oncol. 2020. PMID: 32185627
2,956 results